首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Deciphering the Active Compounds and Mechanisms of Qixuehe Capsule on Qi Stagnation and Blood Stasis Syndrome: A Network Pharmacology Study
【24h】

Deciphering the Active Compounds and Mechanisms of Qixuehe Capsule on Qi Stagnation and Blood Stasis Syndrome: A Network Pharmacology Study

机译:祁县胶囊上的活性化合物和机制对齐停滞和血瘀综合征:网络药理学研究

获取原文
           

摘要

Background. Qixuehe capsule (QXH), a Chinese patent medicine, has been demonstrated to be effective in the treatment of menstrual disorders. In traditional Chinese medicine (TCM) theory, qi stagnation and blood stasis syndrome (QS-BSS) is the main syndrome type of menstrual disorders. However, the pharmacodynamic effect of QXH in treating QS-BSS is not clear, and the main active compounds and underlying mechanisms remain unknown. Methods. A rat model of QS-BSS was established to evaluate the pharmacodynamic effect of QXH. Thereafter, a network pharmacology approach was performed to decipher the active compounds and underlying mechanisms of QXH. Results. QXH could significantly reduce the rising whole blood viscosity (WBV) and plasma viscosity (PV) but also normalize prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (FIB) content in QS-BSS rats. Based on partial least-squares-discriminant analysis (PLS-DA), the low-dose QXH-intervened (QXH-L) and the high-dose QXH-intervened (QXH-H) groups seemed the most effective by calculating the relative distance to normality. Through network pharmacology, QXH may improve hemorheological abnormality mainly via 185 compounds-51 targets-28 pathways, whereas 184 compounds-68 targets-28 pathways were associated with QXH in improving coagulopathy. Subsequently, 25 active compounds of QXH were verified by UPLC-Q/TOF-MS. Furthermore, 174 active compounds of QXH were shared in improving hemorheological abnormality and coagulopathy in QS-BSS, each of which can act on multiple targets to be mainly involved in complement and coagulation cascades, leukocyte transendothelial migration, PPAR signaling pathway, VEGF signaling pathway, and arachidonic acid metabolism. The attribution of active compounds indicated that Angelicae Sinensis Radix (DG), Paeoniae Radix Rubra (CS), Carthami Flos (HH), Persicae Semen (TR), and Corydalis Rhizoma (YHS) were the vital herbs of QXH in treating QS-BSS. Conclusion. QXH can improve the hemorheology abnormality and coagulopathy of QS-BSS, which may result from the synergy of multiple compounds, targets, and pathways.
机译:背景。 Qichuehe胶囊(QXH)是一种中国专利医学,已被证明是有效治疗月经障碍。在中医(中医)理论中,气停滞和血瘀证(QS-BSS)是主要综合症类型的月经障碍。然而,QXH治疗QS-BSS的药效表法尚不清楚,并且主要活性化合物和下面的机制仍然未知。方法。建立了QS-BSS的大鼠模型,以评估QXH的药效效应。此后,进行网络药理学方法以破译QXH的活性化合物和底层机制。结果。 QXH可以显着降低全血粘度(WBV)和血浆粘度(PV)的上升,而且在QS-中归一化凝血酶原时间(PV),激活的部分血栓形成时间(APTT),凝血酶时间(TT)和纤维蛋白原(FIB)含量BSS大鼠。基于部分最小二乘判别分析(PLS-DA),低剂量QXH干预(QXH-L)和高剂量QXH干预(QXH-H)组似乎是通过计算相对距离来最有效的正常。通过网络药理学,QXH主要可以通过185个化合物-51靶-28途径来改善血液流变异常,而184个化合物-68靶-28途径与改善凝结病变的QXH有关。随后,通过UPLC-Q / TOF-MS验证25个活性QXH的化合物。此外,在提高QS-BS中的血液流变异常和凝血病中,共用174个活性化合物,每个QS-BSS中的血管病变都可以采用多种靶标,主要涉及补体和凝血级联,白细胞转诊迁移,PPAR信号通路,VEGF信号通路,和花生酸代谢。活性化合物的归属表明,Angelicae sinensis adrix(dg),paeoniae radix rubra(cs),carthami flos(hh),persicae semen(tr)和corydalis lrizoma(yhs)是治疗Qs-BS的重要草药。结论。 QXH可以改善QS-BSS的血液流变异常和凝血病,这可能是由多种化合物,靶标和途径的协同作用引起的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号